BioSpace News Archive

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277)

Aldeyra Therapeutics, Inc., a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences.

SURE Retractors Inc., a medical devices company founded in Glasgow, Scotland, has raised over $1.5M in its series seed round to develop and launch the SURE retractor product pipeline.Concentra Capital Group, LLC acted as the company’s exclusive financial advisor in connection with the capital raise.

Albireo Pharma, Inc., a rare pediatric liver disease company developing novel bile acid modulators, announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, announced that Craig Thompson, President and Chief Executive Officer, will present at the Wells Fargo Virtual Healthcare Conference and participate in one-on-one meetings with investors.

Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s etrasimod programs.

Secarna Pharmaceuticals GmbH & Co. KG and Evotec SE have expanded their strategic partnership in the field of ASO-based therapeutics.